12/2
07:33 pm
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock.
11/12
04:01 pm
knsa
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Low
Report
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
11/2
01:15 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at
Report
11/2
01:15 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at
Report
10/29
02:28 pm
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $45.00 to $55.00. They now have a "buy" rating on the stock.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $45.00 to $55.00. They now have a "buy" rating on the stock.
10/28
01:13 pm
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock, up previously from $44.00.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $48.00 price target on the stock, up previously from $44.00.
10/28
07:30 am
knsa
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Medium
Report
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
10/23
04:01 pm
knsa
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
Low
Report
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
10/17
11:38 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Citigroup Inc. from $45.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Citigroup Inc. from $45.00 to $50.00. They now have a "buy" rating on the stock.
10/17
08:00 am
knsa
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
Low
Report
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
10/13
09:05 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wedbush from $38.00 to $44.00. They now have an "outperform" rating on the stock.
Medium
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wedbush from $38.00 to $44.00. They now have an "outperform" rating on the stock.
10/8
07:28 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
9/29
10:13 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $60.00 price target on the stock.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is now covered by analysts at TD Cowen. They set a "buy" rating and a $60.00 price target on the stock.
9/25
10:01 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wells Fargo & Company from $42.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target raised by analysts at Wells Fargo & Company from $42.00 to $45.00. They now have an "overweight" rating on the stock.
9/7
03:09 am
knsa
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by analysts at
Low
Report
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was upgraded by analysts at
Report